Nuwellis reports a 28% revenue increase in Q3 2024, driven by its Aquadex therapy focus.

Nuwellis, a medical device company, reported preliminary results for Q3 2024, highlighting a 28% revenue increase in the Pediatric sector, a 70% gross margin, and a 30% reduction in operating costs compared to 2023. The company is focused on the Aquadex ultrafiltration therapy, which has shown increased efficacy. Nuwellis will release full results and hold an earnings call on November 11, 2024.

November 01, 2024
3 Articles

Further Reading